SpaceX IPO is the biggest IPO in stock market history. Join the conversation.Click here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGooch & Housego Regulatory News (GHH)

Share Price Information for Gooch & Housego (GHH)

Share Price is delayed by 15 minutes
Get Live Data
992.00    0.00 (0.00%)
Bid:
0.00
Ask:
0.00
Spread: 16.00 (1.646%)
Market Cap: £271.52m
GHH Live PriceLast checked at - London Stock Exchange

Intraday Gooch & Housego Share Chart

Half Year Trading Update

4 Apr 2023 07:00

RNS Number : 2222V
Gooch & Housego PLC
04 April 2023
 

 

For immediate release

4 April 2023

 

Gooch & Housego PLC

("G&H" or the "Company" or the "Group")

 

Half Year Trading Update

 

"Trading in line with management's expectations"

 

Gooch & Housego PLC (AIM: GHH), the specialist manufacturer of photonic components & systems, provides an update on trading for the six months ended 31 March 2023.

 

Trading

 

In the first half of the financial year the Group made good progress in adding additional capacity to our production facilities. Output levels have increased and we have made steady progress in reducing the level of our overdue order book.

 

Revenue for the six month period is expected to be circa £71.0 million (31 March 2022: £54.1 million) supported by favourable exchange rate movements and the effects of price increases to offset cost input inflation. As previously reported, the progress we have made with recruitment and the supply chain actions we have taken, mean we expect trading this year to be more evenly weighted between the two halves of the financial year than in prior years.

 

New orders for the Group's products from our semiconductor, data communications and next generation industrial laser markets have continued to be strong. We have secured important new programme positions with medical diagnostic customers which will replace other programmes that are now coming to the end of their life cycle. Requests for quotations for the replenishment of equipment that has been deployed into Ukraine are accelerating and we anticipate some of these will convert to new orders shortly. As previously communicated, whilst there is evidence that some of the Group's customers in certain industrial and medical laser sub markets are overstocked we expect this position to rectify itself in the second half of the financial year due to underlying end market demand.

 

As at 31 March 2023 our order book stood at £124.4 million (31 March 2022: £119.9 million), an increase of 3.8%, or a reduction of 0.1% at constant currency, compared with the same time last year. This order book provides good coverage for our expected second half revenues.

 

The Group continues to experience high input cost inflation. In order to ensure we remain competitive in the employment market we have made further upward adjustments to salary levels. We have also seen continued cost inflation from our supply chain. Our commercial team remain focused on passing on these higher costs through pricing and this will support the Group's performance in the second half of this financial year.

 

We remain in a strong financial position with a robust balance sheet and low net debt. At the half year net debt was circa £19m and the Group had $46.2m available from existing committed and uncommitted debt facilities to fund its future growth activities.

 

We expect trading for the full year to be in line with management's previously reported expectations. 

 

 

 

 

Review of the Group's strategy and interim results date

 

The review of the Group's strategy is progressing according to plan. Initial findings have been shared with the Board and we expect to provide more information when the Group's interim results for the six months ended 31 March 2023 are announced on 6 June 2023.

 

 

Charlie Peppiatt, Chief Executive Officer of Gooch & Housego, commented:

 

"I am pleased with the progress that has been made in the first half of the financial year with increasing operational output to better address the demand for our products as well as continued positive levels of customer engagement on next generation programmes and new product opportunities in all our main end markets. This is thanks to the hard work of our employees across the Group and means we are well placed to meet management's expectations for the full year.

 

 "We are on track with our review of the Group strategy and expect to be able to provide more information along with the interim results in June 2023."

 

For further information please contact:

 

Charlie Peppiatt, Chief Executive Officer

Chris Jewell, Chief Financial Officer 

Gooch & Housego PLC

+44 (0) 1460 256440

 

Mark Court / George Cleary

G&H@buchanan.uk.com

Buchanan

+44 (0) 20 7466 5000

 

Christopher Baird / David Anderson

Investec Bank plc

+44 (0) 20 7597 5970

 

 

Notes to editors

 

1. Gooch & Housego is a photonics technology business headquartered in Ilminster, Somerset, UK with operations in the USA and Europe. A world leader in its field, the company researches, designs, engineers and manufactures advanced photonic systems, components and instrumentation for applications in the Aerospace & Defence, Industrial, Life Sciences and Scientific Research sectors. World leading design, development and manufacturing expertise is offered across a broad range of complementary technologies.

 

2. All financial information included in this announcement is sourced from unaudited management accounts and excludes any specific items. This announcement contains certain forward-looking statements that are based on management's current expectations or beliefs as well as assumptions about future events. These are subject to risk factors associated with, amongst other things, the economic and business circumstances occurring from time to time in the countries and sectors in which G&H operates. It is believed that the expectations reflected in these statements are reasonable but they may be affected by a wide range of variables which could cause actual results, and G&H's plans and objectives, to differ materially from those currently anticipated or implied in the forward-looking statements. Investors should not place undue reliance on any such statements. Nothing in this announcement should be construed as a profit forecast.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TSTSSLFMDEDSEDL
Date   Source Headline
3rd Jun 20267:00 amRNSDirectorate change
2nd Jun 20267:00 amRNSInterim Results
20th May 20267:00 amRNSNotice of Half Year Results
10th Apr 20262:25 pmRNSHolding(s) in Company
9th Apr 20267:00 amRNSHalf Year Trading Update
20th Mar 20263:16 pmRNSHolding(s) in Company
27th Feb 20262:23 pmRNSResult of AGM
27th Feb 20267:00 amRNSAGM Trading Update
2nd Feb 20267:00 amRNSChief Financial Officer appointment date
22nd Jan 20262:26 pmRNSHolding(s) in Company
13th Jan 20264:41 pmRNSHolding(s) in Company
12th Jan 20264:34 pmRNSPDMR notice
12th Jan 20263:30 pmRNSGrant of LTIP awards
9th Jan 20267:00 amRNSPDMR Notice and Issue of Equity
7th Jan 20267:00 amRNSPosting of Annual Report and Notice of AGM
12th Dec 20257:00 amRNSAppointment of Chief Financial Officer
2nd Dec 202511:36 amRNSDirector/PDMR Shareholding
2nd Dec 20257:00 amRNSResults for the year ended 30 September 2025
25th Nov 20257:00 amRNSNotification of Full Year Results
20th Nov 20252:14 pmRNSHolding(s) in Company
4th Nov 20257:07 amRNSDirectorate Update
8th Oct 20257:00 amRNSFurther Issue of Shares and TVR
7th Oct 20257:00 amRNSFull Year Trading Update
1st Oct 20252:15 pmRNSHolding(s) in Company
21st Jul 20257:00 amRNSChief Financial Officer Transition
15th Jul 20255:08 pmRNSHolding(s) in Company
30th Jun 20257:00 amRNSNotification of Major Holdings
23rd Jun 20252:30 pmRNSHolding(s) in Company - Replacement
20th Jun 202512:08 pmRNSHolding(s) in Company
18th Jun 20257:00 amRNSCompletion of Acquisition & Total Voting Rights
3rd Jun 20257:00 amRNSInterim Results
20th May 20257:00 amRNSNotification of Half Year Results
14th May 20257:00 amRNSAcquisition of Global Photonics
9th Apr 20252:16 pmRNSHolding(s) in Company
8th Apr 20257:00 amRNSHalf Year Trading Update
24th Feb 20252:19 pmRNSResult of AGM
24th Feb 20257:00 amRNSAGM Trading Update
7th Jan 20252:58 pmRNSGrant of LTIP Awards
6th Jan 202511:15 amRNSPosting of Annual Report and Notice of AGM
20th Dec 20243:15 pmRNSHolding(s) in Company
3rd Dec 20247:00 amRNSResults for the year ended 30 September 2024
4th Nov 20247:00 amRNSNotification of Full Year Results
30th Oct 20247:00 amRNSAcquisition of Phoenix Optical
28th Oct 20242:35 pmRNSHolding(s) in Company
8th Oct 20247:00 amRNSFull Year Trading Update
26th Sep 202410:31 amRNSDirector/PDMR Shareholding
23rd Aug 202412:52 pmRNSNotification of Major Holdings
16th Aug 20245:46 pmRNSHolding(s) in Company
16th Aug 20244:49 pmRNSHolding(s) in Company
15th Aug 20244:33 pmRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.